Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) m |
||
Line 161: | Line 161: | ||
|style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | |style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | ||
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#31a354"|''' | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Classical Hematology''' |
|- | |- | ||
|rowspan=6 style="background-color:#F0F0F0"|[[File:Shruti.jpg|thumb|upright=0.4|center]] | |rowspan=6 style="background-color:#F0F0F0"|[[File:Shruti.jpg|thumb|upright=0.4|center]] |
Revision as of 19:17, 10 January 2018
We are in the process of developing an editorial board of clinical experts, organized primarily by disease focus. Many disease sites now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
Peter C. Yang, MD Boston, MA Twitter: Hem_Onc |
Deputy Editor
Jeremy L. Warner, MD, MS Nashville, TN Twitter: Hemoncwarner |